Academic literature on the topic 'T315I mutation'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'T315I mutation.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "T315I mutation"
Chen, Jiaqi, Hongxing Liu, Fang Wang, Yang Zhang, Xue Chen, Daijing Nie, Yu Li, Yincheng Tan, Yuanli Xu, and Xiaoli Ma. "Dynamic Evolution of Ponatinib Resistant BCR-ABL1 T315 and Compound Mutations." Blood 134, Supplement_1 (November 13, 2019): 3796. http://dx.doi.org/10.1182/blood-2019-129579.
Full textManrique, Gonzalo, Roberta Bittencout, Verónica Pérez, Vanesa Sholl, Monica Cappetta, Noel Zubillaga, Rocio Hassan, et al. "Detection of BCR-ABL Kinase Domain Mutations in Chronic Myeloid Leukemia Patients Treated with Tirosin-Kinase Inhibitors." Blood 112, no. 11 (November 16, 2008): 4261. http://dx.doi.org/10.1182/blood.v112.11.4261.4261.
Full textSoverini, Simona, Giovanni Martinelli, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Gianantonio Rosti, Costanza Bosi, et al. "Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts)." Blood 108, no. 11 (November 16, 2006): 836. http://dx.doi.org/10.1182/blood.v108.11.836.836.
Full textSmith, Catherine C., Michael Brown, Jason Chin, Corynn Kasap, Sara Salerno, Lauren E. Damon, Kevin Travers, et al. "Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy,." Blood 118, no. 21 (November 18, 2011): 3752. http://dx.doi.org/10.1182/blood.v118.21.3752.3752.
Full textShah, Neil P., John M. Nicoll, Susan Branford, Timothy P. Hughes, Ronald L. Paquette, Moshe Talpaz, Claude Nicaise, Fei Huang, and Charles L. Sawyers. "Molecular Analysis of Dasatinib Resistance Mechanisms in CML Patients Identifies Novel BCR-ABL Mutations Predicted To Retain Sensitivity to Imatinib: Rationale for Combination Tyrosine Kinase Inhibitor Therapy." Blood 106, no. 11 (November 16, 2005): 1093. http://dx.doi.org/10.1182/blood.v106.11.1093.1093.
Full textDeininger, Michael W. N., Michael J. Mauro, Yousif Matloub, Ritwik Sinha, Lynn Ploughman, David Liu, and Jerald Radich. "Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML)." Blood 112, no. 11 (November 16, 2008): 3236. http://dx.doi.org/10.1182/blood.v112.11.3236.3236.
Full textKim, Dong-Wook, Dongho Kim, Soo-Hyun Kim, Saengsuree Jootar, Hyun-Gyung Goh, Jeong Lee, Soo-Young Choi, Young-Seok Lee, and Sang-Mi Oh. "Dynamics and Characteristics of BCR-ABL Multiple Mutations In Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia." Blood 116, no. 21 (November 19, 2010): 3443. http://dx.doi.org/10.1182/blood.v116.21.3443.3443.
Full textDeininger, Michael W. N., Jorge E. Cortes, Dong-Wook Kim, Franck E. Nicolini, Moshe Talpaz, Michele Baccarani, Martin C. Müller, et al. "Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 7001. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.7001.
Full textJabbour, Elias, Hagop Kantarjian, Dan Jones, Srdan Verstovsek, Alessandra Ferrajoli, Farhad Ravandi, Susan O’Brien, and Jorge Cortes. "Characteristics and Outcome of Patients with Chronic Myeloid Leukemia (CML) and T315I Mutation Following Failure of Imatinib Mesylate Therapy." Blood 110, no. 11 (November 16, 2007): 1943. http://dx.doi.org/10.1182/blood.v110.11.1943.1943.
Full textJabbour, Elias, Hagop Kantarjian, Dan Jones, Megan Breeden, Guillermo Garcia-Manero, Susan O'Brien, Farhad Ravandi, Gautam Borthakur, and Jorge Cortes. "Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy." Blood 112, no. 1 (July 1, 2008): 53–55. http://dx.doi.org/10.1182/blood-2007-11-123950.
Full textDissertations / Theses on the topic "T315I mutation"
Nagao, Rina. "Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65 - a novel Wnt/β-catenin signaling inhibitor." Kyoto University, 2012. http://hdl.handle.net/2433/157488.
Full textLee, Oi-Lin. "The role of cytokines in governing the expansion of the T315I mutation in chronic myeloid leukaemia." Thesis, 2014. http://hdl.handle.net/2440/95313.
Full textThesis (M.Phil.) -- University of Adelaide, School of Medicine, 2014
Book chapters on the topic "T315I mutation"
Noronha, Glen, Jianguo Cao, Chun Chow, Elena Dneprovskaia, Linda Hwang, Dan Lohse, Chi Ching Mak, et al. "Targeting Drug Resistant Mutations Using Novel Binding Interactions - Lessons Learned from Abl-T315I and their Implications in D." In Frontiers in Drug Design & Discovery (Volume 3), 121–44. BENTHAM SCIENCE PUBLISHERS, 2012. http://dx.doi.org/10.2174/978160805201110703010121.
Full textConference papers on the topic "T315I mutation"
Hong, Soon-Sun, Soo Jung Kim, Kyung Hee Jung, Hong Hua Yan, Zhenghuan Fang, Joo Han Lim, and Jeong Seon Ryu. "Abstract 5389: Novel kinase inhibitor for imatinib-resistant chronic myeloid leukemia with T315I mutation." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-5389.
Full textGupta, Pranav, Guannan Zhang, Anna Maria Barbuti, Ke Ding, Jingxuan Pan, Brian J. Druker, and Zhe-Sheng Chen. "Abstract 1980: S116836 overcomes BCR-ABL T315I mutation mediated imatinib resistance in chronic myeloid leukemia." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1980.
Full textZhu, Xiaotian, Tianjun Zhou, William C. Shakespeare, Wei-Sheng Huang, Lois Commodore, Chester A. Metcalf, Yihan Wang, et al. "Abstract 2671: Structural analysis of the inhibitory mechanism of AP24534, a pan-BCR-ABL inhibitor overriding the T315I gatekeeper mutation." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2671.
Full textGupta, Pranav, Rishil Kathawala, Liuya Wei, Fang Wang, XiaoKun Wang, Brian J. Druker, Li-Wu FU, and Zhe-Sheng Chen. "Abstract 4158: Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through a novel BCR-ABL inhibitor." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-4158.
Full text